Literature DB >> 11520721

The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands.

T L Feenstra1, M L van Genugten, R T Hoogenveen, E F Wouters, M P Rutten-van Mölken.   

Abstract

Chronic obstructive pulmonary disease (COPD) causes extensive disability, primarily among the elderly. On the World Health Organization ranking list of disability-adjusted life years (DALYs), COPD rises from the twelfth to the fifth place from 1990 to 2020. The purpose of this study is to single out the impact of changes in demography and in smoking behavior on COPD morbidity, mortality, and health care costs. A dynamic multistate life table model was used to compute projections for the Netherlands. Changes in the size and composition of the population cause COPD prevalence to increase from 21/1,000 in 1994 to 33/1,000 in 2015 for men, and from 10/ 1,000 to 23/1,000 for women. Changes in smoking behavior reduce the projected prevalence to 29/1,000 for men, but increase it to 25/ 1,000 for women. Total life years lost increase more than 60%, and DALYs lost increase 75%. Costs rise 90%; smokers cause approximately 90% of these costs. The model demonstrates the unavoidable increase in the burden of COPD, an increase that is larger for women than for men. The major causes of this increase are past smoking behavior and the aging of the population; changes in smoking behavior will have only a small effect in the nearby future.

Entities:  

Mesh:

Year:  2001        PMID: 11520721     DOI: 10.1164/ajrccm.164.4.2003167

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  55 in total

1.  Roflumilast (daliresp): a novel phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.

Authors:  Jordan Baye
Journal:  P T       Date:  2012-03

2.  [COPD today and in the year 2020].

Authors:  Bernd Lamprecht; Michael Studnicka
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

3.  Deaths from chronic obstructive pulmonary disease in France, 1979-2002: a multiple cause analysis.

Authors:  C Fuhrman; E Jougla; J Nicolau; D Eilstein; M-C Delmas
Journal:  Thorax       Date:  2006-05-31       Impact factor: 9.139

4.  Secondhand Tobacco Smoke and COPD Risk in Smokers: A COPDGene Study Cohort Subgroup Analysis.

Authors:  Ian van Koeverden; Paul D Blanc; Russell P Bowler; Mehrdad Arjomandi
Journal:  COPD       Date:  2014-07-01       Impact factor: 2.409

5.  Pharmacoeconomic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy.

Authors:  O Zaniolo; S Iannazzo; L Pradelli; M Miravitlles
Journal:  Eur J Health Econ       Date:  2010-11-18

6.  Lung function and blood markers of nutritional status in non-COPD aging men with smoking history: a cross-sectional study.

Authors:  Nobuyoshi Shiozawa; Kanae Hayashimoto; Etsuji Suzuki; Hiroshi Kikuchi; Shingo Takata; Kozo Ashida; Masutaka Watanabe; Yasuhiro Hosaki; Fumihiro Mitsunobu
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-08-09

Review 7.  Self-management education for patients with chronic obstructive pulmonary disease: a systematic review.

Authors:  E Monninkhof; P van der Valk; J van der Palen; C van Herwaarden; M R Partridge; G Zielhuis
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

8.  Present and future costs of COPD in Iceland and Norway: results from the BOLD study.

Authors:  R Nielsen; A Johannessen; B Benediktsdottir; T Gislason; A S Buist; A Gulsvik; S D Sullivan; T A Lee
Journal:  Eur Respir J       Date:  2009-04-08       Impact factor: 16.671

9.  [The prevalence of COPD in Austria--the expected change over the next decade].

Authors:  Natalie Firlei; Bernd Lamprecht; Lea Schirnhofer; Bernhard Kaiser; Michael Studnicka
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

10.  A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease.

Authors:  Maureen P M H Rutten-van Mölken; Floortje E van Nooten; Marion Lindemann; Manfred Caeser; Peter M A Calverley
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.